| Overview |
| bsm-51675M |
| HIF1AN Monoclonal Antibody |
| WB, IF, ICC |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| KLH conjugated synthetic peptide derived from human HIF1AN |
| 1-349/349 |
| Monoclonal |
| L8U9 |
| 0.5ug/ul |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 55662 |
| Q9NWT6 |
| Nucleus |
| Hypoxia inducible factor asparagine hydroxylase; Factor inhibiting HIF1; FIH 1; FIH-1; FIH1; Hypoxia inducible factor 1 alpha inhibitor; Hypoxia inducible factor 1 alpha subunit inhibitor; Peptide aspartate beta dioxygenase; DKFZp762F1811; FLJ20615; FLJ22027; HIF1N_HUMAN. |
| Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminaltransactivation domain (CAD). Functions as an oxygen sensor and,under normoxic conditions, the hydroxylation prevents interactionof HIF-1 with transcriptional coactivators includingCbp/p300-interacting transactivator. Involved in transcriptionalrepression through interaction with HIF1A, VHL and histonedeacetylases. Hydroxylates specific Asn residues within ankyrinrepeat domains (ARD) of NFKB1, NFKBIA, NOTCH1, ASB4, PPP1R12A andseveral other ARD-containing proteins. Also hydroxylates Asp andHis residues within ARDs of ANK1 and TNKS2, respectively.Negatively regulates NOTCH1 activity, accelerating myogenicdifferentiation. Positively regulates ASB4 activity, promotingvascular differentiation. |
| Application Dilution |
| WB |
=1:500-4000，ICC=1:25，IF=1:25， |
| IF |
|
| ICC |
1:100-500 |
Powered by Bioz